Considerable Variation in Cost of Generic Topical Corticosteroids

Share this content:
Considerable Variation in Cost of Generic Topical Corticosteroids
Considerable Variation in Cost of Generic Topical Corticosteroids

THURSDAY, Aug. 20, 2015 (HealthDay News) -- There is considerable variation in the unit cost of topical corticosteroids across potencies and by branded generic or generic product, according to a research letter published online Aug. 19 in JAMA Dermatology.

Alexander Skojec, from the Penn State Hershey College of Medicine, and colleagues examined variation in costs of generic topical corticosteroids of various potencies. They retrospectively analyzed the Truven Health MarketScan Commercial Claims and Encounters Database, which offered data for health insurance claims paid by about 100 payers for more than 120 million U.S. individuals. The copayment and average wholesale price (AWP) for medications were extracted.

The researchers observed variation in the cost of topical corticosteroids across potencies, class, and by branded generic or generic product. For branded generic products, claims were less frequent and had higher copayment and AWP. Among generic topical corticosteroids in the same class there were considerable cost differences; for example, a 15-g or 30-g tube of triamcinolone acetonide 0.01 percent had a mean cost that was 30 to 40 percent lower than other mid-potency medications. Different size tubes of the same medication also differed in the price per gram. Copayments were three to five times higher for branded generic products versus generic products with the same ingredient and unit size.

"Health care professionals may preserve high-quality patient care while reducing cost for the patient by being aware of the differences in generic medications," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »